

## MD Anderson Ovarian SPORE publications – 2015

1. Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G. **Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.** *Oncotarget* 6(6):4266-73, 2015. PMID: PMC4414188.
2. Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G. **The ZNF304-integrin axis protects against anoikis in cancer.** *Nat Commun* 6:7351, 2015. PMID: 26081979.
3. Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, Damoush L, Aust S, Sood AK, Lutgendorf SK. **Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma.** *Brain Behav Immun*, e-Pub 5/2015. PMID: 25989110.
4. Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK. **Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.** *Breast J* 21(3):260-7, 2015. PMID: 25789811.
5. Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AK. **Differential platelet levels affect response to taxane-based therapy in ovarian cancer.** *Clin Cancer Res* 21(3):602-10, 2015. PMID: PMC4315757.
6. Carvalho S, Lindzen M, Lauriola M, Shirazi N, Sinha S, Abdul-Hai A, Levanon K, Korach J, Barshack I, Cohen Y, Onn A, Mills G, Yarden Y. **An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.** *Oncogene*, e-Pub 4/2015. PMID: 25915843.
7. Chen HH, Chen WC, Liang ZD, Tsai WB, Long Y, Aiba I, Fu S, Broaddus R, Liu J, Feun LG, Savaraj N, Kuo MT. **Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.** *Expert Opin Ther Targets*:1-11, e-Pub 5/2015. PMID: 26004625.
8. Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. **Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.** *Cancer Metastasis Rev* 34(1):19-40, 2015. PMID: PMC4369424.
9. Choi MJ, Cho KH, Lee S, Bae YJ, Jeong KJ, Rha SY, Choi EJ, Park JH, Kim JM, Lee JS, Mills GB, Lee HY. **hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness.** *Oncogene* 34(26):3402-12, 2015. PMID: 25151968.
10. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. **A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.** *Gynecol Oncol* 137(3):386-91, 2015. PMID: PMC4447525.
11. Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM. **The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.** *Gynecol Oncol* 136(1):25-9, 2015. PMID: 25448453.
12. Daly MB, Drescher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH. **Salpingectomy as a Means to Reduce Ovarian Cancer Risk.** *Cancer Prev Res (Phila)* 8(5):342-348, 2015. PMID: PMC4417454.

13. Gershenson DM. **Molecular targeting of low-grade serous and mucinous carcinomas of the ovary or peritoneum.** *Transl Cancer Res* 4(1):29-39, 2015.
14. Gómez-Hidalgo NR, Martínez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT. **Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.** *Gynecol Oncol* 137(3):553-558, 2015. PMID: 25827290.
15. Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein G. **Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.** *Clin Cancer Res* 21(9):2127-37, 2015. PMCID: PMC4417466.
16. Groen RS, Gershenson DM, Fader AN. **Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.** *Gynecol Oncol* 136(2):373-83, 2015. PMID: 25481800.
17. Haria D, Trinh BQ, Ko SY, Barengo N, Liu J, Naora H. **The Homeoprotein DLX4 Stimulates NF- $\kappa$ B Activation and CD44-Mediated Tumor-Mesothelial Cell Interactions in Ovarian Cancer.** *Am J Pathol*, e-Pub 6/2015. PMID: 26067154.
18. Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergeant P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugge JS, Mills GB. **Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.** *Nat Commun* 6:7419, 2015. PMID: 26080861. PMCID: PMC4473807.
19. Kuchenbaecker KB, Ramus SJ, ... Perkins J, Platte R, Ellis S; EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM; GEMO Study Collaborators, Damiola F, ... Rookus MA, Oosterwijk JC; Breast CancerFamily Registry, Tihomirova L, ... Hogervorst FB; HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR; KConFab Investigators, Pankratz VS, ... Domchek SM, Lu KH, Karlan BY, Walsh C, Walsh C, Lester J; Australian Cancer Study (Ovarian Cancer Investigators); Australian Ovarian Cancer Study Group, Hein A, ... Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeny LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY, Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1 and BRCA2. **Identification of six new susceptibility loci for invasive epithelial ovarian cancer.** *Nat Genet* 47(2):164-71, 2015. PMCID: PMC4445140.
20. Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györfy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R. **Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.** *Oncogene* 34(3):373-83, 2015. PMCID: PMC4112176.
21. Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Spiewankiewicz B, Myers EJ, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Ekici AB, Hein A, Vergote I, Van

Nieuwenhuysen E, Lambrechts D, Wicklund KG, Eilber U, Wang-Gohrke S, Chang-Claude J, Rudolph A, Sucheston-Campbell L, Odunsi K, Moysich KB, Shvetsov YB, Thompson PJ, Goodman MT, Wilkens LR, Dörk T, Hillemanns P, Dürst M, Runnebaum IB, Bogdanova N, Pelttari LM, Nevanlinna H, Leminen A, Edwards RP, Kelley JL, Harter P, Schwaab I, Heitz F, du Bois A, Orsulic S, Lester J, Walsh C, Karlan BY, Hogdall E, Kjaer SK, Jensen A, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Southey MC, Giles GG, Bruinsma F, Wu X, Hildebrandt MA, Lu K, Liang D, Bisogna M, Levine DA, Weber RP, Schildkraut JM, Iversen ES, Berchuck A, Terry KL, Cramer DW, Tworoger SS, Poole EM, Olson SH, Orlow I, Bandera EV, Bjorge L, Tangen IL, Salvesen HB, Krakstad C, Massuger LF, Kiemeny LA, Aben KK, van Altena AM, Bean Y, Pejovic T, Kellar M, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Lubinski J, Gronwald J, Cybulski C, Jakubowska A, Wentzensen N, Brinton LA, Lissowska J, Yang H, Nedergaard L, Lundvall L, Hogdall C, Song H, Campbell IG, Eccles D, Glasspool R, Siddiqui N, Carty K, Paul J, McNeish IA, Sieh W, McGuire V, Rothstein JH, Whittemore AS, McLaughlin JR, Risch HA, Phelan CM, Anton-Culver H, Ziogas A, Menon U, Ramus SJ, Gentry-Maharaj A, Harrington P, Pike MC, Modugno F, Rossing MA, Ness RB, Pharoah PD, Stram DO, Wu AH, Pearce CL. **Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.** *Gynecol Oncol* 136(3):542-8, 2015. PMID: 25528498.

22. Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. **Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers.** *J Natl Cancer Inst* 107(7), 2015. PMID: 25995442.
23. Matsuo K, Yoshino K, Hasegawa K, Murakami R, Ikeda Y, Adachi S, Hiramatsu K, Yokoyama T, Nishimura M, Sheridan TB, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Fotopoulou C, Roman LD, Sood AK. **Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.** *Gynecol Oncol* 136(2):198-204, 2015. PMID: 25497604.
24. Meyer LA, Nick AM, Shi Q, Wang XS, Williams L, Brock T, Iniesta MD, Rangel K, Lu KH, Ramirez PT. **Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients.** *Gynecol Oncol* 136(3):440-5, 2015. PMID: 25647455.
25. Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. **XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.** *Clin Cancer Res*, e-Pub 4/2015. PMID: 25878333.
26. Nick AM, Coleman RL, Ramirez PT, Sood AK. **A framework for a personalized surgical approach to ovarian cancer.** *Nat Rev Clin Oncol* 12(4):239-45, 2015. PMID: 25707631.
27. Ovarian Cancer Association Consortium, Australian Cancer Study, Australian Ovarian Cancer Study Group. **Genome-wide significant risk associations for mucinous ovarian carcinoma.** *Nat Genet*, e-Pub 6/2015. PMID: 26075790.
28. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A, Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H, Breast Cancer Family Register, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KB, Collée JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Silva ID, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejertsen B, Ekici AB, Ellis SD, EMBRACE, Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley BL, Friebel T, Friedman E, Friel G, Frost D, Garber J, García-Closas M, Gayther SA, GEMO Study

Collaborators, GENICA Network, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goodman MT, Gore M, Greene MH, Grip M, Gronwald J, Gschwantler Kaulich D, Guénel P, Guzman SR, Haerberle L, Haiman CA, Hall P, Halverson SL, Hamann U, Hansen TV, Harter P, Hartikainen JM, Healey S, HEBON, Hein A, Heitz F, Henderson BE, Herzog J, T Hildebrandt MA, Høgdall CK, Høgdall E, Hogervorst FB, Hopper JL, Humphreys K, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A, Jense... **No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.** *Gynecol Oncol*, e-Pub 5/2015. PMID: 25940428.

29. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. **Preclinical and clinical development of siRNA-based therapeutics.** *Adv Drug Deliv Rev*, e-Pub 2/2015. PMID: 25666164.
30. Plamadeala V, Kelley JL, Chan JK, Krivak TC, Gabrin MJ, Brower SL, Powell MA, Rutherford TJ, Coleman RL. **A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.** *Gynecol Oncol* 136(1):94-8, 2015. PMID: 25462203.
31. Previs R, Leath CA 3rd, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA. **Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.** *Gynecol Oncol*, e-Pub 5/2015. PMID: 26037898.
32. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, CIMBA Consortium, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmal M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen Tv, Ramón y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, De Paepe A, Poppe B, Claes K, De Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomäki K, van der Hout AH, ... **Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.** *JAMA* 313(13):1347-61, 2015. PMID: 25849179.
33. Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmouh L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. **Diurnal cortisol and survival in epithelial ovarian cancer.** *Psychoneuroendocrinology* 53:256-67, 2015. PMID: PMC4440672.
34. Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. **Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.** *Oncogene*, e-Pub 2/2015. PMID: 25639871.
35. Shadfan BH, Simmons AR, Simmons GW, Ho A, Wong J, Lu KH, Bast RC Jr, McDevitt JT. **A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.** *Cancer Prev Res (Phila)* 8(1):37-48, 2015. PMID: PMC4465398.

36. Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, Mezzanzanica D, Chen KX, Sood AK, Yang D, Zhang W. **Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer.** *Chin J Cancer* 34(1):28-40, 2015. PMID: PMC4302087.
37. Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. **MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.** *J Pathol* 235(1):25-36, 2015. PMID: PMC4268369.
38. Tuna M, Ju Z, Smid M, Amos CI, Mills GB. **Prognostic relevance of acquired uniparental disomy in serous ovarian cancer.** *Mol Cancer* 14(1):29, 2015. PMID: PMC4320828.
39. Vergote IB, Marth C, Coleman RL. **Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.** *Cancer Metastasis Rev* 34(1):41-52, 2015. PMID: 25564455.
40. Wang Y, Ye Y, Lin J, Meyer L, Wu X, Lu K, Liang D. **Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome.** *Mol Carcinog* 54(6):430-9, 2015. PMID: 25867973.
41. Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. **Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.** *Clin Cancer Res* 21(2):448-59, 2015. PMID: PMC4297546.
42. Yang X, Shen F, Hu W, Coleman RL, Sood AK. **New ways to successfully target tumor vasculature in ovarian cancer.** *Curr Opin Obstet Gynecol* 27(1):58-65, 2015. PMID: 25502429.
43. Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, Li Z, Bast RC Jr, Le XF. **Clinically Relevant microRNAs in Ovarian Cancer.** *Mol Cancer Res* 13(3):393-401, 2015. PMID: PMC4369176.
44. Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH. **Death-associated protein kinase 1 promotes growth of p53-mutant cancers.** *J Clin Invest*, e-Pub 6/2015. PMID: 26075823.